3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Squamous Cell Carcinoma of Head and Neck
5
Tongue Neoplasms
4
Head and Neck Neoplasms
4
Prostatic Neoplasms
3
Pancreatic Neoplasms
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasms, Squamous Cell
1
Mucositis
1
Mouth Neoplasms
1
Laryngeal Neoplasms
1
Hypopharyngeal Neoplasms
1
Glioma
1
Glioblastoma
1
Esophageal Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma
1
Breast Neoplasms
1
Adenocarcinoma
1
Interventions
Gemcitabine
3
Nivolumab
2
temoporfin
1
spartalizumab
1
polysaccharide-K
1
pembrolizumab
1
nimotuzumab
1
devimistat
1
dalotuzumab
1
bemarituzumab
1
belinostat
1
Transurethral Resection of Prostate
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy
1
Radiofrequency Ablation
1
Oxaliplatin
1
Morphine
1
Methadone
1
Leucovorin
1
Ipilimumab
1
Interviews as Topic
1
Injections
1
Immunotherapy
1
Heavy Ion Radiotherapy
1
Fluorouracil
1
Erlotinib Hydrochloride
1
Docetaxel
1
Cryosurgery
1
Cisplatin
1
Brachytherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Adenocarcinoma
×
Radiotherapy, Intensity-Modulated
×
Clear all
NCT03536182
2021-05-26
CIPHER
University of Texas Southwestern Medical Center
Phase 3
Withdrawn